Redeye provides its first take on Camurus’ Q2 report 2026, published this morning. Buvidal sales and Brixadi royalties were clearly above our forecast. Revenues increased by 32% Q/Q, and by 4% Y/Y. The EBIT increased to SEK294m, in line with the previous year, but a strong increase from the previous quarter (SEK293m in Q2 2025 and SEK168m in Q1 2026). Overall, the report exceeds our expectations as we had not expected Buvidal sales to recovery so quickly, while Brixadi royalties were in line with our forecasts.
LÄS MER
